About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 127 results
2020
Z. DeFilipp, Burns, L. J., Jaglowski, S. M., Leppin, A. L., Pavletic, S., Waldman, B., Weisdorf, D. J., Wood, W. A., and Khera, N., A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703., Biol Blood Marrow Transplant, vol. 26, no. 12, pp. e305-e308, 2020.
J. E. Levine, Antin, J. H., Allen, C. E., Burroughs, L. M., Cooke, K. R., Devine, S., Heslop, H., Nakamura, R., Talano, J. An, Yanik, G., and DiFronzo, N., Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network., Biol Blood Marrow Transplant, vol. 26, no. 5, pp. e94-e100, 2020.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
S. A. Holstein, Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N., Green, D. J., Hillengass, J., Korde, N., Li, Z., Mailankody, S., Neri, P., Parekh, S., Pasquini, M. C., Puig, N., G Roodman, D., Samur, M. Kemal, Shah, N., Shah, U. A., Shi, Q., Spencer, A., Suman, V. J., Usmani, S. Z., and McCarthy, P. L., Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 10, pp. e247-e255, 2020.
S. A. Holstein, Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L., and McCarthy, P. L., Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 1, pp. e7-e15, 2020.
S. Giralt, Costa, L. J., Maloney, D., Krishnan, A., Fei, M., Antin, J. H., Brunstein, C., Geller, N., Goodman, S., Hari, P., Logan, B., Lowsky, R., Qazilbash, M. H., Sahebi, F., Somlo, G., Rowley, S., Vogl, D. T., Vesole, D. H., Pasquini, M., and Stadtmauer, E., Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial., Biol Blood Marrow Transplant, vol. 26, no. 4, pp. 798-804, 2020.
2019
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial., Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
A. Rashidi, Shanley, R., Anasetti, C., Waller, E. K., Scott, B. L., Blazar, B. R., and Weisdorf, D. J., Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD., Bone Marrow Transplant, vol. 54, no. 3, pp. 490-493, 2019.
A. Rashidi, Luo, X., Cooley, S., Anasetti, C., Waller, E. K., Brunstein, C. G., Cichocki, F., Weisdorf, D. J., and Miller, J. S., The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples., Blood Adv, vol. 3, no. 16, pp. 2465-2469, 2019.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial., J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
J. Paul, Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., Wu, J., Kim, H., Blazar, B., Ritz, J., Howard, A., Cutler, C., and Miklos, D., A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation., Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
M. Gooptu, Kim, H. T., Howard, A., Choi, S. W., Soiffer, R. J., Antin, J. H., Ritz, J., and Cutler, C. S., Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clini, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2143-2151, 2019.
M. J. Levis, Bin Chen, Y. -, Hamadani, M., Horowitz, M. M., and Jones, R. J., FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?, J Clin Oncol, vol. 37, no. 19, pp. 1604-1607, 2019.
A. A. King, McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., and Shenoy, S., Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601., Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
E. K. Waller, Logan, B. R., Fei, M., Lee, S. J., Confer, D., Howard, A., Chandrakasan, S., Anasetti, C., Fernando, S. M., and Giver, C. R., Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation., Blood Adv, vol. 3, no. 15, pp. 2250-2263, 2019.
S. A. Holstein, J Ye, C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., C Landgren, O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K., and McCarthy, P. L., Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 25, no. 3, pp. e89-e97, 2019.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with , Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
2018
S. G. Holtan, DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, C. S., Arai, S., Lazaryan, A., Newell, L. F., Jagasia, M. H., Pusic, I., Wood, W. A., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Bunworasate, U., Efebera, Y. A., Ferrara, J. L. M., Pidala, J., Howard, A., Wu, J., Bolaños-Meade, J., Ho, V., Alousi, A., Blazar, B. R., Weisdorf, D. J., and MacMillan, M. L., Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802., Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
A. Rashidi, Wangjam, T., Bhatt, A. S., Weisdorf, D. J., and Holtan, S. G., Antibiotic practice patterns in hematopoietic cell transplantation: A survey of blood and marrow transplant clinical trials network centers., Am J Hematol, vol. 93, no. 11, pp. E348-E350, 2018.
A. Rashidi, Shanley, R., Yohe, S. L., Thyagarajan, B., Curtsinger, J., Anasetti, C., Waller, E. K., Miller, J. S., Blazar, B. R., and Weisdorf, D. J., Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples., Bone Marrow Transplant, vol. 53, no. 8, pp. 1069-1071, 2018.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials., Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
S. A. Holstein, Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K., and McCarthy, P. L., BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee., Biol Blood Marrow Transplant, vol. 24, no. 4, pp. 641-648, 2018.
L. M. Turcotte, DeFor, T. E., Newell, L. F., Cutler, C. S., Verneris, M. R., Wu, J., Howard, A., MacMillan, M. L., Antin, J. H., Vercellotti, G. M., Slungaard, A., Blazar, B. R., Weisdorf, D. J., Panoskaltsis-Mortari, A., and Holtan, S. G., Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402., Bone Marrow Transplant, vol. 53, no. 1, pp. 64-68, 2018.
R. Spellecy, Tarima, S., Denzen, E., Moore, H., Abhyankar, S., Dawson, P., Foley, A., Gersten, I., Horwitz, M., Idossa, L., Joffe, S., Kamani, N., King, R., Lazaryan, A., Morris, L., Horowitz, M. M., and Majhail, N. S., Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study., Biol Blood Marrow Transplant, vol. 24, no. 10, pp. 2145-2151, 2018.
M. J. Martens and Logan, B. R., A group sequential test for treatment effect based on the Fine-Gray model., Biometrics, vol. 74, no. 3, pp. 1006-1013, 2018.